Selected abstracts from the 2002 American Society of Hematology convention
Compiled by Greg Dafoe

[email protected]

4609 120 Ki Y. Chung

Enforced Expression of Nup98-HoxA9 in Human

CD34+ Cells Provides a Proliferative Advantage

and Enhances Stem Cell Self Renewal. Acute Myeloid



944 128 Hongxiang Liu

Characterisation of the Genomic Breakpoint in

t(11;18)(q21;q21) of MALT Lymphoma.


1133 129 Hongtao Ye

High Incidence of t(11;18)(q21;q21) in Helicobacter Pylori Negative Gastric MALT Lymphoma.


4345 130 Ellen D. Remstein

Primary Pulmonary MALT Lymphomas Show

Frequent and Heterogeneous Cytogenetic Abnormalities, Including a Previously Unreported MALT1-IGH Translocation.


2737 131 Irit Avivi

Histological and Clinical Prognostic Factors in

Follicular Lymphoma: Proposal for a Prognostic


2559 137 Mauricette Michallet

Autologous and Allogeneic Hematopoietic Stem

Cell Transplantations (HSCT: AutoT and AlloT)

Versus Conventional Chemotherapy in Chronic Lymphocytic Leukemia (CLL): An European Blood and Marrow Transplant (EBMT) and French CLL Cooperative Group Study. Transplantation


3978 138 Sharon Avery

Type 2 Dendritic Cell (DC2) Content in Donor

Peripheral Blood Stem Cell (PBSC) Grafts Is

Associated with Improved Survival Following

Allogeneic Transplantation. Transplantation


3357 139 Emma Morris

Long-Term Follow-Up of an Alemtuzumab (CAMPATH-1H) -Containing Reduced Intensity

Allogeneic Transplant Regimen for Non- Hodgkins Lymphoma (NHL).


921 140 Rowena D. Bainton

Reduced Intensity Allogeneic Transplantation

Using BEAM-Campath in Patients with Lymphoproliferative Disease-GVHD, Toxicity

and Survival in 65 Patients.


579 141 Jianmin Wang

Allogeneic Peripheral Blood Stem Cell Transplantation for the Treatment of Leukemia:

A New Regimen for Acute GVHD Prophylaxis.


5024 146 Kenneth Cornetta

Umbilical Cord Blood Transplantation in Adults:

Results of a Prospective, Multi-Institutional, NHBLI Sponsored Trial. Clinical Results:


2104 147 Juliet N. Barker

Rapid and Complete Donor Chimerism in Adult

Recipients of Unrelated Donor Umbilical Cord Blood Transplantation after Non-Myeloablative Conditioning.


2220 148 Vanderson Rocha

Results of Unrelated Cord Blood Versus Unrelated Bone Marrow Transplant in Adults with Acute Leukemia. A Matched Pair Analysis.


2122 260 Benny J. Chen

Differential Effects of Naive and Non-Naive T Cells on GVHD: Implications in Separating GVL from GVHD.


5167 277 Roberto Rodriguez A

Fludarabine/Melphalan (Flu/Mel) Reduced Intensity Conditioning Regimen with Cyclosporine and Mycophenolate Mofetil (CSA/MMF) Allows Successful Transplantation of Patients Who Are Not Candidates for

Standard Unrelated Donor Transplantation (URD BMT).


282 278 Yoshinobu Kanda

Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Mismatched Family Donors over the Last Decade.


2054 279 Renate Arnold

Allogeneic Stem Cell Transplantation from HLAIdentical

Sibling Donor in High Risk ALL Patients Is Less Effective Than Transplantation from Unrelated Donors.


3187 280 Vanderson Rocha

Outcomes of HLA Identical Siblings Are Comparable to Unrelated Bone Marrow Tansplants in Adults with Acute Lymphoblastic Leukemia.


340 332 Izidore S. Lossos

GAL Is a Novel IL-4-Inducible Gene That Strongly Predicts Survival in Diffuse Large B-Cell Lymphoma.


934 337 Georges Fillet

Radiotherapy Is Unnecessary in Elderly Patients with Localized Aggressive Non Hodgkins Lymphoma: Results of the GELA LNH 93-4 Study.


2682 338 Maria Alma Rodriguez

A Phase II Study of Liposomal Vincristine in CHOP with Rituximab for Patients with Untreated Aggressive B-Cell Non- Hodgkin[s Lymphoma (NHL): A Safe and Effective Combination.


2750 339 Wolfgang Hiddemann

The Addition of Rituximab (R) to Combination Chemotherapy (CT) Significantly Improves the Treatment of Mantle Cell Lymphomas (MCL): Results of Two Prospective Randomized Studies by the German Low Grade Lymphoma Study Group (GLSG).


4434 340 Michael Pfreundschuh

2-weekly vs. 3-weekly CHOP with and without Etoposide in Young Patients with Low-Risk (low LDH) Aggressive Non-Hodgkins Lymphoma: Results of the Completed NHL-B-1 Trial of the DSHNHL.



3688 342 Lorenz H. Truemper

Significant Dose Escalation of the CHOEP Regimen in Young Patients with Aggressive Non Hodgkin[ssquote]s Lymphoma Is Feasible: Results of a Prospective Randomized Phase I/II Trial.


3173 343 Felix Reyes

Superiority of Chemotherapy Alone with the ACVBP Regimen over Treatment with Three Cycles of CHOP Plus Radiotherapy in Low Risk Localized Aggressive Lymphoma: The LNH93-1 GELA Study.


113 344 Pier Luigi Zinzani

A Multicenter Randomized Trial of Fludarabine and Mitoxantrone (FM) Plus Rituximab Versus CHOP Plus Rituximab as First-Line Treatment in Patients with Follicular Lymphoma (FL).


2767 401 Carmelo Carlo-Stella

Use of Recombinant Human Growth Hormone

(rhGH) Plus Recombinant Human Granulocyte

Colony-Stimulating Factor (rhG-CSF) for the

Collection of CD34+ Cells in poor mobilizers


4946 412 Raymond Powles

Predictive Model Based on Day 7 Parameters

To Predict the Risk of Treatment Related Mortality (TRM) in Patients Undergoing Allogeneic Hematopoetic-Stem Cell Transplant (AHSCT).


1580 415 Francis J. Giles

A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study (RPCDBM) of Iseganan HCL Oral Solution (Iseganan) in Reducing Severity of Oral Mucositis (OM) in Patients (pts) Receiving Stomatotoxic

Chemotherapy (CT).


1581 416 Brian J. Bolwell

Survival after Allogeneic BMT: The Prognostic Importance of the Platelet Count 100 Days Post- Transplant.


165 417 A. Urbano-Ispizua

Chronic Graft Versus Host Disease after Allogeneic Transplantation of CD34+ Selected Cells from Peripheral Blood from HLA-Identical Siblings.


1548 418 Brian J. Bolwell

Secondary Malignancy after Autologous Stem Cell Transplantation (ABMT) for Non- Hodgkins Lymphoma and Hodgkins Disease Using a Busulfan Containing Preparative Regimen.


1398 419 Mario Arpinati

Infusion of High Numbers of G-CSF Mobilized Blood Dendritic Cells Type 2 (DC-2) Is Associated with an Increased Rate of Chronic GVHD in Allogeneic PBSC Transplantation.


5033 420 Christele K. Ferry

Treatment of B-Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. Role and Immunological Follow-Up of Rituximab.


1552 535 Matthias Edinger

Donor CD4+CD25+ Regulatory T Cells Suppress Acute GVHD Lethality without Loss of GVL Activity.


4111 536 Petra Hoffmann

CD4+CD25+ Regulatory T Cells Act in Secondary Lymphoid Organs To Protect from Lethal Acute GVHD.


4122 537 Lianne Marks

Regulatory CD8 T Cells Can Fratricidally Eiminate Donor T Cells Utilizing Fas Ligand and Perforin Following Allogeneic Bone Marrow Transplantation.


4150 538 Stephen C. Jones

Post-Hematopoietic Cell Transplant Control of Graft-Versus-Host Disease by Donor CD4+CD25+ T Cells To Allow an Effective Graft-Versus-Leukemia Response.


5053 539 Persis J. Amrolia

Selective Depletion of Donor Allo-Reactive TCells

without Loss of Anti-Viral and Anti- Leukemic Responses Using an Anti-CD25 Immunotoxin.


878 540 Fiona J. Clark

Chronic Graft Versus Host Disease Is Associated with Increased Numbers of CD4+CD25+ T Lymphocytes.


3083 541 Stephen P. Robinson

Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin[ssquote]s Disease: An Analysis from the European Group for Blood and Marrow Transplantation.


5105 542 Charles Crawley

Reduced Intensity Conditioned Allografts for Myeloma: A Study from the Chronic Leukaemia Working Party of the EBMT.


3661 543 Paolo Corradini

Reduced-Intensity Conditioning Followed by Allogeneic Transplantation (HSCT) Is an Effective Salvage Treatment for Both Low- and High-Grade Non-Hodgkin Lymphomas: Disease Chemosensitivity Has a Major Impact on Outcome.

5103 544 Brenda M. Sandmaier

Low Dose TBI Conditioning for Hematopoietic Stem Cell Transplants (HSCT) from HLAMatched Related Donors for Patients with Hematologic Malignancies: Influence of

Fludarabine or Cytoreductive Autografts on Outcome.

1175 545 Mary Eapen

Increased Chronic Graft Versus Host Disease and Mortality after Peripheral Blood Stem Cell Transplantation in Older Children and Adolescents with Acute Leukemia.


1031 546 Sophia B. Randolph

Impact of Donor/Patient Gender on Relapse and Graft Versus Host Disease in Matched Related Hematopoietic Stem Cell Transplant.


809 590 Wen-Kai Weng

Rituximab-Induced Antibody-Dependent Cellular

Cytotoxicity (ADCC) in Follicular Non- Hodgkins Lymphoma.


2949 591 Francisco Hernandez-Ilizaliturri

Enhancement in Anti-Tumor Activity of Rituximab When Combined with Epratuzumab or Apolizumab (Hu1D10) in a B-Cell Lymphoma Severe Combined Immunodeficiency (SCID) Mouse Model.


2962 595 Dieter Hoelzer

Successful Treatment of Burkitt[ssquote]s NHL and Other High-Grade NHL According to a Protocol for Mature B-ALL.


1144 600 Joachim Yahalom

H. Pylori-Independent MALT Lymphoma of the Stomach: Excellent Outcome with Radiation Alone

1331 601 Reda Bouabdallah

T-Cell/Histiocyte-Rich Large B-Cell Lymphomas and Classical Diffuse Large B-Cell Lymphomas Have Similar Responsiveness to Chemotherapy: A Matched-Control Analysis on 50 Patients.


2259 602 Emilio Iannitto

Splenic Marginal Zone Lymphoma with or without Villous Lymphocytes. Hematological Findings and Outcome in a Series of 57 Patients.


726 603 Nicolas Mounier

Rituximab Plus CHOP (R-CHOP) in the Treatment of Elderly Patients with Diffuse Large B-Cell lLmphoma (DLBCL) Overcomes Bcl2- Associated Chemotherapy Resistance.


1067 604 Michele Ghielmini

Prolonged Treatment with Rituximab Significantly Improves Event Free Survival and Duration of Response in Patients with Follicular Lymphoma: A Randomised SAKK Trial.


1341 606 Johannes Drach

Marked Anti-Tumor Activity of Rituximab Plus Thalidomide in Patients with Relapsed/Resistant Mantle Cell Lymphoma.


4008 607 Susan J. Knox

A Phase I Dose Optimization Study of Anti- CD20 Pretarget Radioimmunotherapy in Patients with Relapsed or Refractory NHL.


1538 608 Wyndham H. Wilson

Idiotype Vaccine Following EPOCH-Rituximab Treatment in Untreated Mantle Cell Lymphoma.


4164 609 Sunil A. Reddy

Plant Derived Single-Chain Fv Idiotype Vaccines Are Safe and Immunogenic in Patients with Follicular Lymphoma: Results of a Phase I Study.


3758 610 Myron S. Czuczman

IDEC-114, an Anti-CD80 Monoclonal Antibody for Relapsed or Refractory, Follicular NHL: Phase I/II Study of Safety, Efficacy, and Pharmacokinetics.


716 627 Andy C. Rawstron

Sub-Clinical CLL Is found in a High Proportion of Normal Relatives from CLL Families: Young Adults Show the Highest Relative Risk.


3686 630 Jenny A. Orchard

Zap-70 Evaluation by Flow Cytometry Is a

Significant Prognostic Marker in B-CLL.


4091 631 Adrian Wiestner

Zap70 Expression Identifies B-CLL with Unmutated Immunoglobulin Genes, Worse Clinical Outcome and a Distinct Gene Expression Profile.


1610 632 Wendelina J.M. Mackus

B Cell Receptor (BCR) Triggering Leads to Enhanced Survival of Leukemic B Cells in BCLL Patients with Unmutated IgVH Genes and Zap-70 Expression.


1337 633 Francesc Bosch

ZAP-70 Expression Is a Reliable Surrogate for Immunoglobulin Variable Region Mutations in Chronic Lymphocytic Leukemia.


4053 651 Ramaprasad Srinivasan

High Response Rate and Improved Survival in Patients with Steroid-Refractory Acute Graft-vs- Host Disease (SRGVHD) Treated with Daclizumab with or without Infliximab.


2945 654 Joseph H. Antin

Combination Sirolimus, Tacrolimus, and Methotrexate To Prevent Graft-vs-Host Disease (GVHD) after Unrelated Donor or Mismatched Family-Member Marrow Transplantation.


5374 655 Steven M. Devine

Impact of GM-CSF Mobilization on the Composition of Donor Allografts and the Risk of Acute GVHD Following HLA-Matched Hematopoietic Cell Transplantation.


663 656 Marco Mielcarek

Graft-Versus-Host Disease after Nonmyeloablative Versus Conventional Hematopoietic Stem Cell  Transplantation.


1848 657 J. J. Cornelissen

Allogeneic T-Cell Depleted (TCD) Blood Stem Cell Transplantation Versus TCD Bone Marrow Transplantation: A Prospective Randomised Multicenter Study.


4272 658 Stefan A. Klein

Diagnosis and Monitoring of Acute Intestinal Graft Versus Host Disease by High Resolution Ultrasonography and Color Doppler Imaging.


1597 659 Bernd Gruhn

Clinical Significance of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation.


3464 662 Sandra Cohen

Reduced Intensity Allogeneic Stem Cell Transplantation for Patients Who Have Failed a Prior Autologous Stem Cell Transplant.


3524 663 K. S. Peggs

Dose Escalating Donor Lymphocyte Infusions (DLI) Following T-Depleted Reduced Intensity Allografting: High Response Rates Associated with Conversion to Full Donor Chimerism (FDC) Are Not Durable Despite Persistent Donor Chimerism.


963 666 Avichai Shimoni

Post-Transplant Rituximab Reduces Relapse Risk after Allogeneic and Autologous Stem-Cell Transplantation (SCT) in High-Risk Aggressive Lymphoma.


525 675 Noel-Jean Milpied

Frontline High-Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation vs Standard CHOP Regimen for Patients (PTS) 60 yo) with Non IPI High-Risk Intermediate or High-Grade Lymphomas (NHL). Final Results of a Randomized Trial by the GOELAMS


1785 676 John W. Strehl

High Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in First- Line Therapy of Aggressive NHL Is Superior to Conventional Chemotherapy in Selected Patients: An Analysis of Published Data in

Terms of Induction Therapy,


5125 677 Amrita Krishnan

Durable Remissions in HIV-Related Lymphoma with Autologous Stem Cell Transplantation.


904 678 Hillard M. Lazarus

Outcome of Autologous Hematopoietic Stem Cell Transplant (AHSCT) Outcome for Non- Hodgkin Lymphoma (NHL) in Patients Age 60 Years or Older.


4634 679 Auayporn Nademanee

A Phase I/II Trial of High-Dose Radioimmunotherapy (RIT) with Zevalin in Combination with High-Dose  Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Stem Cell Transplant (ASCT) in

Patients with Poor-Risk or Relapsed B-Cell Non-Hodgkins


5218 680 Arturo Molina

Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL): A Report of 69 Patients from City of Hope (COH) and Stanford.


1286 681 Gustaaf W. van Imhoff

Short Intensified Therapy and Autologous Stem Cell Transplantation in Adult Burkitt Lymphoma. Excellent Results without High-Dose MTX.


3601 682 Peter Mollee

Autologous Stem Cell Transplantation (ASCT) for Relapsed /Refractory Follicular Large Cell Lymphoma (FLCL).


504 696 Derek S. Serna

Trends in Survival Rates by Race after Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia in the United States and Canada.


2154 752 Daniela Capello

Lack of Simian Virus 40 (SV40) Infection in Lymphoid Malignancies: A Reappraisal Based on 500 Cases from Southern Europe.


1503 775 Stefan Faderl

Combined Use of Alemtuzumab and Rituximab in Patients with Relapsed and Refractory Chronic Lymphoid Malignancies - An Update of the M.D. Anderson Experience.


4823 794 Steven P. Treon

Combination Therapy with Rituximab and Fludarabine Is Highly Active in Waldenstroms Macroglobulinemia.


2377 799 Martin Bornhaeuser

Conditioning with Fludarabine and Targeted Busulfan before Transplantation of Allogeneic Hematopoietic Stem Cells.


4632 806 K. A. Marr

Itraconazole vs. Fluconazole for Antifungal Prophylaxis in Allogeneic HSCT Recipients: Results of a  Randomized Trial.


498 1217 Annuska M. Glas

Prognostic Stratification and Transformation of Follicular Lymphoma, a Microarray Study.


4351 1218 Stephen C. Schmechel

Identification of Genes Whose Expression Patterns Distinguish Low-Grade Lymphomas.


2997 1219 Catherine Thieblemont

Classification and Prognosis of Diffuse Small B-Cell Lymphomas by Gene Expression Profile.


4033 1222 Sean P. Bohen

Predicting Rituximab Response of Follicular Lymphoma Using cDNA Microarray Analysis.


5370 1223 Ulf Klein

Gene Expression Profile Analysis of AIDSRelated

Non-Hodgkin Lymphomas.


3229 1227 John Shaughnessy

Gene Expression Profiling of CD19 and CD138-Enriched Cells from Waldenstroms Macroglobulinemia (WM) Reveals Distinct Classes and Novel WM-Specific Genes.


4398 1346 Derek Leitch

Waldenstrom[ssquote]s Macroglobulinemia Is Characterised by a Memory B-Cell Immunophenotype and the Absence of Immunoglobulin Translocations.


3832 1349 Nilima Parry-Jones

Interphase FISH Study of Trisomy 12 and 13q14 Deletions in Mantle Cell Lymphoma with Leukaemia; Comparison with CLL and SLVL.


929 1352 Hideko Goto

A High Serum Soluble Interleukin-2 Receptor Level Is Associated with a Poor Prognosis of Aggressive and Indolent Non- Hodgkin[ Lymphoma.


5242 1358 Alessandra Cesano

Differential Expression of CD22 in Indolent and Aggressive Non-Hodgkins Lymphoma (NHL): Implications for Targeted Immunotherapy.


1793 1359 Motoko Yamaguchi

Prognostic Significance of CD21 Expression in Diffuse Large B-Cell Lymphomas.


901 1360 Judit M. Joergensen

Prognostic Significance of Angiogenesis in Specific Lymphoma Subtypes.


3449 1363 Sharon L. Barrans

NF[kappa]B Is Associated with Non-Germinal Center Diffuse Large B Cell Lymphoma and Is a Poor Prognostic Factor.


2129 1364 Stephen M. Ansell

Inhibition of Survivin Expression Suppresses the Growth of Transformed Large Cell Non-Hodgkin Lymphoma.


2952 1367 Purvi Gada

Epratuzumabs Predominant Antitumor Activity n Vitro/In

Vivo Against Non-Hodgkins Lymphoma (NHL) Is Via Antibody- Dependent Cellular Cytotoxicity (ADCC).


957 1368 Wen-Kai Weng

Analysis of IgG Fc Receptor Fc RIIIa Polymorphism in Relapsed Follicular Non-Hodgkins Lymphoma Patients

Treated with Rituximab.


5571 1372 D. Gwyn Bebb

Effect of Cyclophosphamide, BCL2 Antisense Oligonucleotides and Rituximab on Mantle Cell Lymphoma Growth in a Murine In Vivo Model.


5081 1375 Matthias Grube

Are Normally Expressed B-Cell Differentiation Antigens Possible Target Antigens for Cellular Immunotherapy in BCell Malignancies?


3993 1381 Mark S. Kaminski

High Response Rates and Durable Remissions in Patients with Previously Untreated, Advanced-Stage, Follicular Lymphoma Treated with Tositumomab and

Iodine I-131 Tositumomab (Bexxar.


4013 1382 Mark S. Kaminski

Bexxar Radioimmunotherapy Produces a Substantial Number of Durable Complete Responses in Patients with Multiply Relapsed or Refractory Low Grade or

Transformed Low Grade Non-Hodgkins Lymphoma.


3397 1383 Charles Redfern

A Phase II Trial of Favid [Id-KLH] for Relapsed Indolent Non-Hodgkins Lymphoma


4070 1384 Andrew D. Zelenetz

Patients with Transformed Low Grade Lymphoma Attain Durable Responses Following Outpatient  Radioimmunotherapy with Tositumomab and Iodine I 131 Tositumomab Bexxar


5144 1385 Sandra J. Horning

Rituximab Treatment Failures: Tositumomab and Iodine I 131 Tositumomab Bexxar Can Produce Meaningful Durable Responses.


4198 1386 Myron Czuczman

Zevalin[ Radioimmunotherapy Is Not Associated with an Increased Incidence of Secondary Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia


5568 1387 Gregory A. Wiseman

Yttrium-90 Zevalin Phase I Sequential Dose Radioimmunotherapy Trial of Patients with Relapsed Low Grade and Follicular B-Cell Non-Hodgkins Lymphoma (NHL): Preliminary Results.


5270 1388 John P. Leonard

Phase I/II Trial of Epratuzumab (Humanized

Anti-CD22 Antibody) in Non- Hodgkins Lymphoma


1611 1389 Upendra Hegde

Phase I Study of Combination Rituximab (CD20) and Apolizumab (Hu1D10) Monoclonal Antibody Therapy in Previously Treated B-Cell Lymphoma and Chronic

Lymphocytic Leukemia.


1716 1390 Bertrand Coiffier

Rituximab Re-Treatment in B-Cell Lymphoma Patients: Efficacy and Toxicity in 59 Patients Treated in One Center.


755 1392 Umberto Vitolo

High Clinical and Molecular Response Rate in Elderly Patients with Advanced Stage Follicular Lymhoma Treated at Diagnosis with a Brief Chemo-Immunotherapy FND + Rituximab.


1132 1393 Amos Cohen

Results of a Phase II Study Employing a Combination of Fludarabine, Cyclophosphamide and Rituximab (FCR) as Primary Therapy for Patients with Advanced Follicular Lymphoma (FL): The Israel Cooperative Lymphoma Group.


1839 1394 Glen A. Kennedy

Incidence and Nature of CD20 Negative Relapses Following Rituximab Therapy in Aggressive B-Cell Non-Hodgkins Lymphoma: A Retrospective Review.


3034 1395 Simona Martin

Eradication of Minimal Residual Disease in Patients with Follicular Lymphoma Depends on the Disease Status and the Type of Cytotoxic Therapy Combined with the Anti- CD20 Monoclonal Antibody (Rituximab) as

Revealed by Molecular Monitoring with Nested and Re


4037 1396 Julie M. Vose

Long Term Follow-Up of a Phase II Study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Aggressive Non- Hodgkins Lymphoma (NHL).


3491 1397 Julie Vose

A Phase 2 Trial To Evaluate the Efficacy of Recombinant Idiotype Vaccine with Abbreviated Course of  ranulocyte-

Macrophage Colony-Stimulating Factor Adjuvant in Follicular Non- Hodgkins Lymphoma.


3694 1398 Thomas E. Witzig

Rituximab Therapy for Patients with Newly Diagnosed, Asymptomatic Advanced-Stage Follicular Grade I Non-Hodgkins Lymphoma (NHL): A Phase II Trial in the North Central Cancer Treatment Group (NCCTG).


4270 1399 Alexandra M. Levine

Fludarabine, Mitoxantrone and Rituxan: An Effective Regimen for the Treatment of Mantle Cell Lymphoma.


1648 1400 Lucio Gordan

A Phase II Trial of Individualized Pharmacokinetic Dosing of Rituximab Maintenance for Patients with CD-20 Positive Lymphoproliferative Disorders.


5188 1401 Stephanie A. Gregory

Combined Fludarabine, Mitoxantrone, and Rituximab Achieves a High Response as Initial Treatment for Advanced Low Grade Non-Hodgkins Lymphoma


557 1402 Carsten Hirt

High Percentage of Molecular Remissions in Advanced Stage Follicular Lymphoma (FL) Patients Treated with Chemoimmunotherapy in Comparison To Chemotherapy Alone.


2393 1403 Nancy L. Bartlett

Phase I Study of SGN-30, a Chimeric Monoclonal Antibody (mAb), in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies.


2446 1405 Nam H. Dang

Phase II Study of Delineukin Diftitox (ONTAK) for Relapsed/Refractory B and T-Cell Non-Hodgkins Lymphoma.


1451 1408 Anas Younes

A Phase II Study of Interleukin-12 (IL-12) in Patients with Relapsed Non-Hodgkin Lymphoma and Hodgkin  disease.


2866 1576 Kraig Abrams

Recombinant Human Macrophage Colony- Stimulating Factor (rhM-CSF) Induced Thrombocytopenia (TCP) in Dogs.


1508 1577 Carmelo Carlo-Stella

Age- and Irradiation-Associated Loss of Bone Marrow Hematopoietic Function Is Reversed by Recombinant Human Growth Hormone (rhGH).



4584 1541 Athanasios B.-T. Fassas

Survival after Relapse Post-Tandem Auto-Transplant (Tx) in Multiple Myeloma (MM) Patients (pts): The Univ. of Arkansas (UAMS) Total Therapy I (TT1) Experience.


157 1542 M. A. Dimopoulos

Treatment of Waldenstrom's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide.


2173 1578 Gabrielle L. Goldberg

Sex Steroid Ablation Enhances Immune Reconstitution Following Allogeneic Bone Marrow Transplantation.


3374 1582 Sylvain Perruche

Mixed Chimerism Following Non-Myeloablative Conditioning Regimen Is Associated with an Increased Frequency of Lupus-Like Circulating Auto-Antibodies and May Favor Occurrence of Chronic Graft- Versus-Host Disease.


4525 1586 Genevieve Osborne

Depletion of Dendritic Cells (DCs) from the Blood and Skin of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplants (allo-HSCT) by Alemtuzumab

Containing Regimens.


1211 1587 Bella Bielorai

Full Hematopoietic Engraftment after Allogeneic Peripheral Blood Stem Cell Transplantation without Conditioning in SCID Patients.


1105 1589 Clarisse Audigier-Valette

Non Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NSCT): Impact of Pretransplant Factors and Chimerism Status on Transplant Outcome with or without Donor Lymphocyte Infusion (DLI).


5419 1593 Juanita M. Shaffer

Peripheral Blood Stem Cell Transplantation Leads to Enhanced T Cell Recovery Compared to BMT in Patients with Advanced Hematological Malignancies

Receiving HLA-Identical Transplantation with Non-Myeloablative Conditioning.


3417 1594 Pamala A. Jacobson

Day Posttransplant Significantly Influences Pharmacokinetics of Cyclosporine Following Hematopoietic Stem Cell Transplantation (HSCT).


1597 Jane N. Winter

Zevalin Dose-Escalation Followed by High-Dose BEAM and Autologous Peripheral Blood Progenitor Cell (PBPC) Transplant in Non-Hodgkins Lymphoma: Early Outcome Results.


3447 1598 William J. Hogan

Frequency and Severity of Hepatic Injury after  conditioning with a Nonmyeloablative Regimen.


2758 1599 Irit Avivi

Neurological Complications Post Low Intensity Bone Marrow Transplantation.


1442 1602 Colleen T. Morton

Pulmonary Thromboembolism Following Bone Marrow Transplantation. A Review of 306 Autopsies.


5036 1603 Natalie S. Callander

Equivalency of Mini Dose vs Standard Dose G-CSF for Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): A Randomized, Double Blind Study.


2184 1605 Aloysius Y.L. Ho

Late Events in Reduced-Intensity Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) with Alemtuzumab (CAMPATH-1H) Containing Regimens Impact on Outcome Compared with Standard Myeloablative Conditioning.


2888 1609 Seong-Jun Choi

Engraftment Syndrome Following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Review of 216 Patients.


3511 1611 Stuart L. Goldberg

Gemtuzumab Ozogamicin (Mylotarg) Prior to Allogeneic Hematopoietic Stem Cell Transplantation Increases the Risk of Hepatic Veno-Occlusive Disease.


5517 1612 J. Hidalgo

Cardiac Arrhythmias Following High-Dose Therapy and Hematopoietic Stem Cell Transplantation: Prevalence and Outcomes.


1737 1613 Bruno C. Medeiros

Fatal Aplasia and Graft Rejection after Nonmyeloablative Allografting.


1085 1619 Robert J. Soiffer

Engraftment, Graft-vs-Host Disease (GVHD), and Survival after CD8+ T Cell Depleted Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).


4133 1623 Peter A. McSweeney

Low Incidence of Early Transplant Mortality Using Tacrolimus and Mycophenolate Mofetil for GVHD Prevention after Conventional Allografting.


225 1624 Mohamad Mohty

Graft-Versus-Host Disease and Graft- Versus-Tumor Effect after HLA-Identical Sibling Transplantation with ATG-Based Reduced Intensity Preparative Regimen.


5287 1626 S. Chakrabarti

Impact of Adding Mycophenolate Mofetil (MMF) to Cyclosporine (CSA) as Prophylaxis for Acute Graft Versus Host Disease (GVHD) Following Nonmyeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation.



367 1627 Renee M.Y. Barge

A Two Step Non-Myeloablative Allogeneic (NM-allo) Transplantation Strategy Using In Vitro T-Cell Depleted G-CSF Mobilized Peripheral Blood Stem Cells Followed by Donor Lymphocyte Infusions (DLI).


5505 1630 Sara P. Gladney

Effect of Donor Dendritic Cells on Overall Survival and Incidence of GvHD after Allogeneic HPCT from HLA Matched Sibling Donors.


294 1631 Laura J. Johnston

GLAT (Copaxone) for Treatment of Steroid-Refractory Acute Graft Versus Host Disease.


2152 1635 Natsu Ogawa

Increased Incidence of Acute Graft-Versus-Host Disease (GVHD) with a Continuous Infusion of Cyclosporine A (CsA) Compared to Twice-Daily Administration.


464 1637 Angelo M. Carella

Alemtuzumab (MabCampath) Can Successfully Treat Steroid-Refractory Acute Graft-Versus-Host Disease (aGVHD).



4165 1638 Vincent T. Ho

Safety and Efficacy of Denileukin Diftitox (ONTAK) in Patients with Steroid Refractory Graft-Versus-Host Disease (GVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).


3747 1639 Issa F. Khouri

Mini-Dose Campath-1H In-Vivo Induces Significant Reduction of GVHD Associated with High-Dose Chemotherapy and Allogenic Transplantation (ASCT).


1803 1640 Tetsuya E. Tanimoto

Comparison of Chronic Graft-Versus-Host Disease (GVHD) Following Allogeneic Bone Marrow (BMT) vs Peripheral Blood Stem Cell Transplantation (PBSCT) in Japanese Patients.


3589 1641 Bimalangshu R. Dey

Comparison of Outcomes after Transplantation of Peripheral Blood Stem Cells (PBSCT) Versus Bone Marrow (BMT) Following an Identical Non-Myeloablative

Conditioning Regimen.


1647 Margit Mitterbauer

Molecular and Clinical Remission after Dose-Reduced and Myeloablative Allogeneic and Syngeneic Stem Cell

Transplantation in Patients with Advanced Non-Hodgkin[ Lymphoma: A Comparative Single Center Study.


4034 1648 Miguel-Angel Perales

Long Term Remission with T-Cell Depleted Marrow Transplants from Related or Unrelated Donors for Advanced Non- Hodgkin Lymphoma (NHL).


467 1649 A. M. Carella

Autologous Stem Cell Transplantation Followed by Immunosuppressive Nonmyeloablative Allografting Induces High Complete Remission in Advanced Hodgkins Disease and Non- Hodgkins Lymphoma.


2851 1650 Masakazu Higuchi

Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Non-Hodgkin Lymphoma (NHL): A Retrospective Survey.


2893 1651 Michael J. Robertson

Safety and Biological Activity of Siplizumab (AlloMune Component II: MEDI-507) in Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (NMAT) for Refractory Non-Hodgkins Lymphoma (NHL).


4968 1652 Issa F. Khouri

Nonablative Allogeneic Stem Cell Transplantation for Relapsed Mantle Cell Lymphoma (MCL): A Promising Strategy for an Aggressive Disease.


5408 1653 W. Blum

Outcomes for Patients with Non- Hodgkins Lymphoma Following Donor Transplantation Using Low Dose, Single Exposure Total Body Irradiation and Cyclophosphamide Conditioning: A Single Institution Experience.



1654 Paolo Corradini

Nonmyeloablative Conditioning Followed by Allogeneic Transplantation Has a Better Outcome Than High-Dose Chemotherapy Plus Autografting in Non Hodgkin

Lymphomas with T-Cell Histology.


1551 1655 Brian J. Bolwell

Efficacy of Allogeneic BMT (Allo BMT) in Non-Hodgkins Lymphoma (NHL).


4255 1656 Eiji Kusumi

Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantaion (RIST) for Non-Hodgkins Lymphoma (NHL): A Feasible Treatment Option.


1664 David F. Claxton

Campath-1H Allows Non-Myelosuppressive Conditioning for Allogeneic Stem Cell Transplantation.


1709 1665 Gunnar Juliusson

Subcutaneous Campath1H Instead of Thymoglobulin in Nonmyeloablative Allogeneic Transplantation: Reduced Acute Toxicity, but Delayed Lymphocyte Recovery

Leading to More Mixed Chimerism, More Fatal Infections and Impaired Long-Term Survival: A Single Center


5032 1666 Chitra Hosing

Second Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Refractory Hematological Malignancies.


1731 1668 R. Powles

7-year Follow-Up of a Randomized Study of Allogeneic Marrow Versus Blood Stem Cell Transplantation: Lower Relapse and Higher Disease-Free Survival with Blood.


1835 1811 Sylvain Choquet

Efficacy and Safety of Rituximab in B-Cell Post Transplantation Lymphoproliferative Disorders (B-PTLD): Preliminary Results of a Multicenter, Open Label, Phase II Trial (M39037 TRIAL).


2292 1812 Sylvain Choquet

Post Transplantation Lymphoproliferation Disorders (PTLD): A Monocentric Clinicopathologic Study of 67 Cases.


1691 1813 Michaela Cerri

Molecular Histogenesis of Plasmablastic Lymphoma of the Oral Cavity.


3239 1817 Alan Astrow

Long-Term Survival in Patients with Human Immunodeficiency Virus Associated Small Non-Cleaved Lymphoma.


5142 1818 Nicholas Golda

AIDS-Related Non-Hodgkins Lymphoma in Females: Clinical, Immunologic and Pathologic Characteristics.


4262 1819 Robert S. Mocharnuk

Characteristics of Rectal Involvement in Patients with AIDS-Related Non-Hodgkins Lymphoma (AIDS-NHL):

Results of a Single Institution Study of 381 Cases.


4281 1820 Robert D. Lieberman

Virologic Response to HAART in AIDS Related Lymphoma Patients Undergoing Front-Line Chemotherapy.


3268 1824 Francois Boue

CHOP Chemotherapy Plus Rituximab in HIV Patients with High Grade Lymphoma Results of an ANRS Trial.


4504 2105 Stephan Mathas

Strong Overexpression of the Putative Oncoprotein Bcl-3 in Anaplastic Large Cell Lymphoma.


4767 2113 Wendy B. Wong

Inhibition of NF-[kappa]B Decreases c-Myc Expression and Enhances Apoptosis of Burkitts Lymphoma Cells in

Response to Treatment with Chemotherapeutic Agents.


4989 2147 Lisa L. Smith

Interphase Cytogenetics Are Predictive of Chronic Lymphocytic Leukemia (CLL) Response to Thrice Weekly Rituximab Therapy.


734 2215 Rifat A. Hamoudi

Different Cellular Origin between Primary Effusion Lymphoma with and without EBV Infection.


189 2216 Guenter Valet

Individualized Risk Assessment for Patients Suffering from Diffuse Large-B-Cell Lymphoma Prior to Chemotherapy.


610 2219 Marco Ladetto

Marked Telomere Length Heterogeneity in Low-Intermediate Grade Non-Hodgkin Lymphomas (LI-NHL).


440 2220 Marco Ladetto

Frequent Detection of Rearrangements Unrelated to Those Observed at Diagnosis in Late Molecular recurrences of Follicular Lymphoma (FL) Patients.


4224 2221 Kenichi Nomura

Chromosome Aberrations Are Predictive Factor for Helicobacter Pylori Eradication Therapy to Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.


947 2227 Michael Jenner

Genetic Risk Factor for Follicular Lymphoma within the MHC Region.


562 2235 Francois Lefrere

Molecular Relapse in Peripheral Blood (PB) Predicts Early Clinical Evolution in Patients with Mantle Cell Lymphoma after Initial Complete Remission: Results from a Prospective Single Center Study.


1960 2239 Michele Spina

Patients (pts) with HIV-Related NHL (HIVNHL) Who Achieve Complete Response (CR) after Chemotherapy (CT) and on HAART Have the Same Outcome as pts with High Grade NHL of the General Population.


1305 2240 Michael Crump

Gemcitabine, Dexamethasone, Cisplatin (GDP) Salvage Chemotherapy for Relapsed or Refractory Hodgkins Disease (HD): A National Cancer Institute of Canada

Clinical Trials Group Study.


728 2241 Charles Dumontet

A Phase I Trial of the P-Glycoprotein (P-gp) Inhibitor Zosuquidar.3HCL (LY335979) and CHOP Chemotherapy in Patients with Non-Hodgkins  Lymphoma.


5067 2243 Andrew M. Evens

Multi-Modality Therapy with a New Chemotherapy Regimen (T-CAP/V-MAC) Followed by Hematopoietic Stem Cell Transplant (HSCT) and Immunotherapy ([alpha]IFN/IL-2) for Mantle Cell Lymphoma (MCL): Prospective Analysis of Response and Toxicity.


3004 2244 Amir Z. Ginzburg

Aggressive Therapy for Leptomeningeal Involvement in Non-Hodgkins Lymphoma.


3773 2245 Timothy D. Moore

A Single Pegfilgrastim Dose Per Cycle Supports Dose-Dense (q14d) CHOP-R in Patients with NHL.


285 2246 Stefano Sacchi

Phase II Study with Fludarabine and Cyclophosphamide Plus Rituximab (FC+R) in Relapsed Follicular Lymphoma Patients.


804 2247 Rudolf Weide

Bendamustine / Mitoxantrone / Rituximab (BMR): A New Effective Treatment for Refractory or Relapsed Indolent



2941 2254 Yong Du

A Radiation Dose Response Exists in Radioimmunotherapy of B-Cell Lymphoma in the Presence of a Signaling Antibody.


1587 2256 Ronald Taylor

Complement (C) Activation Is Required for Rituximab (RTX) Mediated Killing of CD20 Positive Cells, and a High Tumor Burden May Decrease Therapeutic Efficacy Due to C Depletion as a Consequence of Therapy.

In Vitro and In Vivo Studies.


1941 2259 Michael Dechant

CD89- Directed Bispecific Antibodies Are Superior to Chimeric IgA Antibodies under Suboptimal Conditions.


1183 2260 David M. Goldenberg

Characterization of New, Chimeric and Humanized, Anti-CD20 Monoclonal Antibodies, cA20 and hA20, with equivalent Efficacy to Rituximab In-Vitro and in Xenografted Human Non-Hodgkins Lymphoma.


5525 2268 Shaji Kumar

Bcl-2 Over-Expression Results in Decreased Measles Virus Mediated Cytotoxicity in Lymphoma Cell Lines.


5209 2269 Adele Fielding

The Anti-Lymphoma Efficacy of Replicating, Attenuated Measles Virus Is Enhanced by Viral Expression of GM-CSF.


4346 2274 Alison McCormick

Enhanced In Vivo Response to an Idiotype Lymphoma Vaccine.


4096 2275 Gwen L. Nichols

Bcl-2 Antisense Treatment for Waldenstroms Macroglobulinemia.


5001 2409 Craig L. Semerad

Direct Activation of Neutrophils by G-CSF Is Not Sufficient To Induce Stem Cell Mobilization.


4296 2420 Pavan Reddy

Pretreatment of Donors with Interleukin-18 Attenuates Acute Graft-Versus-Host Disease Via STAT6 and Preserves Graft-Versus-Leukemia Effect.


3216 2435 Rob M. Verdijk

Reinfusion of Autologous Thrombocytes Recovered from Peripheral Blood Stem Cell (PBSC) Harvests in Healthy Related Donors Enables Multiple Day Large Volume



358 2436 Jenny F. Abrahamsen

Better Preservation of Early Hematopoietic Progenitor Cells (LTC-IC) When Peripheral Blood Progenitor Cells (PBPC) Are Cryopreserved with 5% as Compared to

10% DMSO.


5238 2441 M. Girgis

Low-Dose (550 cGy), Single-Exposure Total Body Irradiation (TBI) with Cyclophosphamide as Conditioning for 99 Patients Undergoing Unrelated Donor (URD) Bone Marrow Transplantation (BMT) Results in a Graft Failure Rate (7.1%) Comparable to That Observed…


2973 2442 C. Carvallo

Prior Chemotherapy (Chemo) Facilitates Donor Engraftment Following Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).


3685 2443 Nicolaus Kroger

Allogeneic Stem Cell Transplantation from Related and Unrelated Donors after a Fludarabine/Melphalan Based Dose-Reduced Conditioning for Patients with Advanced Stage II/III Multiple Myeloma.


2024 2444 Paolo Anderlini

Reduced Early Transplant-Related Mortality Following Allogeneic Stem Cell Transplantation (SCT) with Fludarabine-Based, Reduced-Intensity Conditioning from

Matched Related and Unrelated Donors in Advanced Hodgkins Disease (HD).


603 2445 Aloysius Y.L. Ho

Reduced-Intensity Allogeneic Haematopoietic Stem Cell Transplantation for Poor Prognosis Myelodysplastic Syndromes Using Fludarabine, Busulphan and CAMPATH-1H (alemtuzumab) Conditioning.


4170 2446 Steven Zivko Pavletic

Immunological Effects of Pentostatin in a Minimally Myelosuppressive Regimen for Allogeneic Stem Cell Transplantation.


5097 2447 Michael R. Bishop

Contribution of T Cells to Engraftment: A Comparison of T Cell Depleted vs. T Cell Replete Allografts after  reduced-Intensity Conditioning.


4030 2449 Scott I. Bearman

Sequential Autologous and Allogeneic Stem Cell Transplantation for Hematologic Malignancies.


4123 2453 Humberto J. Caldera

Allogeneic Progenitor Cell Transplantation (PCT) for High-Risk Patients with Advanced Hematologic Malignancies Using Fludarabine (Flu) Plus Non-Myeloablative Doses (NMD) of Intravenous (IV) Busulfan

(Bu). Results of a Phase I/II Trial.


1539 2457 C. Faucher

Reduced Intensity Conditioning Regimen for Allogeneic Transplantation in Elderly Patients with Advanced Diseases Is Associated with Good Outcome and Low

Transplant-Related Toxicity.


1039 2458 Seah H. Lim

Ultralite Allogeneic HSCT: Towards a Chemotherapy-Free Outpatient Transplant Regimen.


4204 2463 Takahiro Fukuda

Allogeneic Hematopoietic Stem Cell Transplantation in Patients with a History of Prior Invasive Aspergillosis: Outcomes and Risks for Post-Transplant Invasive



3980 2464 Takahiro Fukuda

Invasive Fungal Infections in Recipients of Nonmyeloablative Hematopoietic Stem Cell Transplantation: Risks and Outcomes.


835 2466 Rowena D. Bainton

Fludarabine Increases the Risk of CMV Infection in Reduced Intensity Allogeneic Transplants Receiving Pre-Transplant Campath.


2871 2470 Evan B. Shereck

Cytomegalovirus (CMV) Prophylaxis with Alternate Day Ganciclovir/Foscarnet in at Risk Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Is 100%

Effective in Preventing CMV Infections and Reducing Ganciclovir Hematopoietic Toxicity.


5181 2476 Francisco M. Marty

Risk of Non-Candida Invasive Fungal Infections in Allogeneic Bone Marrow Transplant Patients Who Received Infliximab To Control Severe GVHD


5140 2477 Tina B. Stacy

Foscarnet for Cytomegalovirus Preemptive Therapy Following Autologous and Allogeneic Hematopoietic Stem Cell Transplantation.


4264 2478 Cynthia L. Toze

Outcome of Sequential Cytomegalovirus (CMV) Prevention Strategies in 3 Consecutive Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Cohorts over 15 Years: Near Elimination of CMV Disease (CMVD), Improvement in Non-Relapse

Mortality (NRM)


5312 2479 Arif R. Alam

Infectious Complications in Long-Term Survivors of Cord Blood Stem Cell Transplantation (CBSCT); Experience at Roswell Park Cancer Institute.


4881 2487 Wolfgang A. Bethge

Donor Lymphocyte Infusions after Nonmyeloablative Marrow Transplantation.


4147 2496 J. Choi

Second Allogeneic Transplant for Relapsed High-Grade Hematologic Malignancies: Early Results on the Feasibility of Using a Different Donor.


4404 2515 Scott D. Rowley

Unrelated Donor Hematopoietic Stem Cell Transplantation after Administration of a Non-Myeloablative Conditioning Regimen of Fludarabine, Rabbit Anti-Thymocyte Globulin (rATG), and Total Body Irradiation (TBI).


4841 2516 Keiichi Isoyama

The Japan Cord Blood Bank Network Experience with Cord Blood Transplantation from Unrelated Donor for Haematological Malignancies: An Impact of GVHD

Prophylaxis for Survival.


3337 2517 Johannes C. Fischer

Outcome of Unrelated Hematopoietic Stem Cell Transplantations: A Comparison between Bone Marrow and Peripheral Blood Obtained from One Donor Center.


4694 2522 Cladd E. Stevens

Does Patient Age Affect Outcome in Cord Blood Transplants? A Retrospective Analysis of 1101 Transplants from the New York Blood Centers National Cord Blood Program.


4852 2523 Vinod Prasad

High-Resolution DNA Typing for HLA-A, -B, and -DRB1 Has Direct Impact on the Survival in the Recipients of Unrelated Donor (URD) Hematopoietic Stem Cell

Transplant (HSCT).


1825 2526 Marcos De Lima

Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) for the Treatment of Myeloid Malignancies in Patients Older Than 55 Years of Age.


1489 2527 Eliane Gluckman

Factors Associated with Outcome of Unrelated Cord Blood Transplant: Guidelines for Donor Choice. An Eurocord Study.


910 2528 Eulogio Conde

Autologous Stem Cell Transplantation (ASCT) in 419 Patients with Follicular Lymphoma (FL).


909 2529 Eulogio Conde

Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL).


1092 2530 Gustaaf W. van Imhoff

IPI Score at Relapse or Progression Is Highly Predictive for Outcome after Autologous Stem Cell Transplantation in Chemosensitive NHL.


5062 2531 Kristie A. Blum

Delayed Neutrophil and Platelet Engraftment Following Autologous Transplantation in Non-Hodgkins Lymphoma Patients Previously Treated with Rituximab.


1028 2532 Wolfram Brugger

Treatment of Follicular and Mantle Cell Lymphoma with Rituximab after High-Dose Chemotherapy and autologous Blood Stem Cell Transplantation: A Multicenter Phase II Study.


3190 2533 Philippe Colombat

Value of Autologous Stem Cell Transplantation in First Line Therapy of Primary CNS Lymphoma.


5079 2534 Christian H. Geisler

Mantle Cell Lymphoma (MCL): Increased Clinical and Molecular Response Rates Adding Ara-C and Rituximab to CHOP + BEAM and Autologous Stem Cell Transplantation. Results of the 1st and 2nd  Nordic MCL Protocols.


1161 2535 Chara A. Kyriacou

Patients with Chemosensitive Angioimmunoblastic Lymphoma (AITL) Can Be Salvaged with Autologous Stem Cell Transplantation, Irrespectively of the

Number of Previous Treatment Lines. Analysis of 74 Cases from the European Bone Marrow Transplant Registry (EB


4564 2536 Thomas S. Lin

Autologous Stem Cell Transplants Result in Better 5-year Overall, but Not Progression-Free, Survival Than Allogeneic Transplants in Patients with Indolent Non-

Hodgkins Lymphoma.


276 2537 Melissa D. Matulis

High Dose Therapy and Autologous Stem Cell Transplant Does Not Result in Long Term Disease Free Survival in Patients with Recurrent Chemotherapy Sensitive Anaplastic Large Cell Lymphoma That Is Anaplastic Lymphoma Kinase Negative.


2557 2538 Issa F. Khouri

Concurrent Administration of High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stem Cell Transplantation (ASCT) for Relapsed B-Cell Lymphomas: Increased Efficacy without Added Toxicity.


3735 2539 Douglas A. Stewart

A Phase II Trial of Front-Line Double High Dose Chemotherapy (HDCT) with DICEP Then BEAM and Autologous Stem Cell Transplantation (ASCT) as Induction Therapy for Poor Prognosis AggressiveNHL

1562 2540 Brian J. Bolwell

The Engraftment Syndrome (ES) May Generate a Graft-Versus-Tumor Effect after Autologous Peripheral Blood Progenitor Cell (PBPC) Transplantation for DLBL


1070 2541 Tarun Kewalramani

Similar Outcomes for Chemosensitive (CS) Relapsed or Primary Refractory Peripheral T-Cell Lymphoma (PTCL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Autologous Transplantation (ASCT).


1511 2542 Sergio Cortelazzo

High-Dose Sequential (HDS) Chemotherapy with High-Dose ARA-C and Rituximab Prolongs the Survival of Patients with Resistant/Relapsed B-Cell Non-Hodgkins Lymphoma.


3434 2543 Leona A. Holmberg

Rituximab and Interleukin 2 for CD20 Positive Non-Hodgkin[scquote]s Lymphoma Following Autologous Transplant.


918 2544 Craig H. Moskowitz

An Analysis of Accelerated Full Course Chemotherapy Followed by Upfront High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Patients with International Prognostic Index IV (IPI

IV) Aggressive NHL.


4020 2545 Ravi A. Madan

Autologous Transplantation for Patients over 60 Years of Age with Non-Hodgkins Lymphoma (NHL). A Case-Control Study.


1576 2546 Corrado Tarella

Rituximab-Supplemented High-Dose Chemotherapy with Autografting in High-Risk B-Diffuse Large Cell Lymphoma: A Multicenter, Prospective Study of GITIL

(Gruppo Italiano Terapie Innovative nei Linfomi).


4766 2547 Rena J. Buckstein

High Dose Therapy/ASCT Consolidated with Rituximab and or Alpha Interferon Immunotherapy for Relapsed Follicular Lymphoma Prolongs Progression Free Survival and Achieves Durable Molecular Remissions.


5555 2548 B. Desablens

First Line ABMT for Primary CNS Lymphoma. Unicentric Experience on 8 Patients.


3949 2549 Pamela Ely

Autologous Peripheral Blood Stem Cell (PBSC) Transplantation for Large Cell NHL: Age but Not Transformation Status Affects Survival.


3821 2550 Giovanni Martinelli

Rituximab Plus Chemotherapy, CD34+ Cell Selection and High-Dose Chemotherapy in Advanced Stage  mantle-Cell Lymphoma.


5353 2551 Moacyr R. Oliveira

Early Lymphocyte Recovery Predicts for Progression-Free Survival (PFS) in Hodgkin Lymphoma (HL) Patients Following Autologous Stem Cell Transplant (ASCT)

Using the Same Ablative Regimen.


520 2552 Alessandro Re

High Dose Therapy (HDT) and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation as Salvage Treatment in HIV-Associated Lymphoma (HIV-Ly).


3769 2553 Jan-Peter Glossmann

Tandem Transplantation with High-Dose Etoposide Mobilized Peripheral Blood Stem Cells in Patients with Primary Progressive Hodgkins and Aggressive Non-

Hodgkins Lymphoma.


1607 2557 Katharine A. Whartenby

Antigen Specific Tumor Immunotherapy Using Gene Modified Bone Marrow.


385 2559 G. Reza Sharifi

NK Cells as New Target for Gene Therapy; Using Retroviral Vectors as Promising Delivery System.


843-II Gene Transfer and New Technologies

4179 2563 Nachimuthu Chinnasamy

Ex Vivo Generation of Genetically Modified Monocyte-Derived Dendritic Cells for Immunotherapy- Implications of Lymphocyte Contamination.


1432 2868 Anas Younes

Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after Paclitaxel Plus Topotecan Chemotherapy in Patients with Relapsed Aggressive Non-Hodgkin



665 2908 Sebastien Lahousse

Structure, Expression, Regulation of the Hematopoietic-Specific RhoH Gene, Involved in the Progression of

Follicular B-Cell Non Hodgkin Lymphomas (NHL).


1802 2909 Momoko Nishikori

High-Level Expression of BCL3 Differentiates t(2;5)(p23;q35)-Positive Anaplastic Large Cell Lymphoma from Hodgkins Disease.


600 3037 Jonathan W. Friedberg

FDG-PET Is Superior to Gallium Scintigraphy in the Staging and Follow-Up of Patients with De Novo

Hodgkin[ Disease: A Prospective, Blinded Comparison.


2877 3038 Marek Trneny

Early Whole Body F18-FDG Positron Emission Tomography (PET) Restaging Has Significant Prognostic Impact in Diffuse Large Cell Lymphomas (DLCL-B) and Other Aggressive Lymphomas.


673 3039 Guy Jerusalem

Does 18F-FDG PET Replace Bone Marrow Biopsy (BMB) in Patients with Hodgkins Disease (HD) or Non-

Hodgkins Lymphoma (NHL)?


5330 3040 Thomas D. Weyburn

FDG-PET Predicts the One Year Progression-Free Survival (1-y PFS) of Patients with Diffuse Large B-Cell

Lymphoma Following Anthracycline-Based Chemotherapy.


2450 3041 Barbara Pro

Positron Emission Tomography Using Fluorodeoxyglucose but Not Gallium-67 Scintigraphy Is a Sensitive Imaging Modality in the Staging of Mantle Cell Lymphoma.


3895 3042 Paul Fields

18FDG-PET Positron Emission Tomography (PET) Is Highly Predictive of Outcome Following Autograft for Relapsed Lymphoma. A Retrospective Study of 41


782 3043 Matthias A. Karajannis

Epstein-Barr Virus Infection in Western European Pediatric Non-Hodgkin Lymphomas.

3180 3046 Philippe Colombat

Validity of the Follicular Lymphoma International Prognostic Index (FLIPI) in All Age Groups.


884 3047 Eric Dryver

Exposures, Hormones, Heredity and the Risk of Non-Hodgkins Lymphoma: Results from a Case-Control  tudy in Southern Sweden.


4665 3050 Francesco A.d’Amore

Grade I-II Follicle Center Lymphoma (FCL) in a Population-Based Danish Case Material: Frequency of Histologic Transformation and Related Outcome.


5479 3051 Francesco A.d’Amore

Non-Hodgkins Lymphoma (NHL) Incidence Related to Histologic Subtype, Immunophenotype and Site of Disease in Western Denmark from 1983 through 1999.


2250 3056 Caroline Besson

Diffuse Large Cell Lymphoma in HCV Positive Patients - A Comparative Study of the French Group of Lymphoma (GELA).


731 3057 Paule-Marie Carli

Association between Hepatitis C and Non Hodgkin Lymphoma.


4605 3060 Michael Pfreundschuh

2-weekly vs. 3-weekly CHOP with and without Etoposide for Patients >60 Years of Age with Aggressive Non-Hodgkins Lymphoma (NHL): Results of the Completed NHL-B-2 Trial of the DSHNHL.


3273 3061 Jan-Peter Glossmann

Effects of Recombinant Human Erythropoietin on Transfusion Requirements in Patients with Relapsed Lymphoma Treated with Aggressive High-Dose

Sequential Chemotherapy.


2662 3063 Owen A. OConnor

Phase II Clinical Experience with the Proteasome Inhibitor PS-341 in Patients with Indolent Lymphomas.


4450 3064 Apostolia-Maria Tsimberidou

Duration of Decreased Absolute Number of Circulating CD4 Cells and CD4/CD8 Ratio in Patients with Indolent Lymphoma Treated with Fludarabine.


749 3065 Michael A. Fridrik

Sequential Alternating Chemotherapy with Cyclophosphamide, Epirubicin, Vincristine, Prednisolon, Ifosfamide, Etoposide, Methotrexate, Dexamethasone, and Filgrastim (CEOP/IMVP-Dexa) vs. Standard

Cyclophosphamide, Vincristine, Doxorubicin, Prednisolon (CHOP


3750 3066 Holger Schulz

Phase-II Trial of Rituximab in Patients with Relapsed CD20-Positive Hodgkins Lymphoma: An Update from the German Hodgkins Lymphoma Study Group (GHSG).


4835 3067 J. Fernandes

Analysis of 98 Relapses of Localized  Aggressive NHL Initially Treated by the GOELAMS 02 & 03 Trials.


5262 3068 Lionel M.L. Chow

Long-Term Survival of Children with Hodgkins Disease Treated with MOPP-ABV and Low-Dose Extended-Field



3817 3069 Bertram Glass

Mega-CHOEP Repeated High Dose Therapy as Treatment of Aggressive NHL: Critical Impact of Time Scheduling.


1068 3070 Kara M. Kelly

BEACOPP Chemotherapy Is an Active and Feasible Regimen in Children and Adolescents with Advanced Stage Hodgkins Disease: Preliminary Results from Childrens Cancer Group Study CCG-59704.


1784 3071 Johanna C. Kluin- Nelemans

Final Results of the EORTC Phase II Trial 20962 Evaluating High-Dose MTX-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-Aids Related Primary Central Nervous System Lymphoma.


5162 3072 Lan Lin

Monitoring Epstein-Barr Virus Load in Peripheral Blood in AIDS-Related Lymphoma Patients: An AIDS malignancy Consortium Laboratory Study.


3912 3073 Giovanni Martinelli

Rituximab Plus Chlorambucil in Low-Grade Non Hodgkins Lymphomas (NHL): Clinical Results of a Phase II Study.


4493 3076 S. Tabuteau

Neurotoxicity of Combined Treatment of Primary CNS NHL: Analysis of 150 Patients Treated by the GOELAMS LCP 88 Trial.


1317 3077 Michael Crump

Gemcitabine, Dexamethasone, Cisplatin for Relapsed or Refractory Non-Hodgkins Lymphoma (NHL): A National Cancer Institute of Canada Clinical Trials Group Study.


936 3078 Jodi L. Grabinski

Substantial Neurotoxicity Associated with Ifosfamide-Containing (ICE) Chemotherapy in Refractory Non-Hodgkins Lymphoma.


4306 3080 Olayemi Agboola

Efficacy of the Colony-Stimulating Factors (CSFs) in Elderly Patients with Aggressive Non-Hodgkins Lymphoma (NHL): A Meta-Analysis.


124 3082 Michael Herold

BOP Versus COP in Advanced Indolent Lymphomas - Results of a Randomized Multicenter Phase III Study of the East German Study Group Hematology/Oncology


706 3083 Lisa Kujawski

HIGH-Dose CHOP and Midcycle Methotrexate for Adult Burkitt and Burkitt-Like Lymphomas.


2909 3085 Gary H. Lyman

Risk and Timing of Hospitalization for Febrile Neutropenia among Patients Receiving CHOP-Like Regimens for Intermediate- Grade Non-Hodgkins Lymphoma.


3774 3086 Sanford Kempin

Randomized Study of Mixed Bacterial Vaccine (MBV) for Follicular Lymphoma (FL): An Evaluation over 20 Years.


2929 3088 Andrew Spencer

Vinorelbine and Gemcitabine with Filgrastim

(VGF) Support Shows Significant Activity Against Advanced Lymphoma.


5347 3165 Kanti R. Rai

Patients with Refractory B-CLL and T-PLL Treated with Alemtuzumab (Campath[reg]) on a Compassionate Basis. A Report on Efficacy and Safety of CAM 511 Trial.


5546 3166 Jan Bole

Combined Rituximab and High-Dose Methylprednisolone for the Treatment of Chronic Lymphocytic Leukemia.


4651 3167 Thomas S. Lin

A Phase I Dose Escalation Study of Apolizumab (Hu1D10) Using a Stepped Up Dosing Schedule in Patients with Chronic Lymphocytic Leukemia (CLL) and Acute Lymphocytic Leukemia (ALL).


4721 3168 Thomas S. Lin

Filgrastim and Alemtuzumab (Campath-1H) for Refractory Chronic Lymphocytic Leukemia: High Frequency of Cytomegalovirus Disease and Delayed



3955 3169 Thomas Elter

Development of a New, Four-Weekly Schedule (FluCam) with Concomittant Application of Campath-1H and Fludarabine in Patients with Relapsed/Refractory CLL.


2467 3171 Robert Drapkin

Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Previously Treated or Untreated Chronic Lymphocytic Leukemia.


1459 3173 Maher Albitar

Correlation between Campath-1H and Response to Therapy in Patients with Chronic Lymphocytic Leukemia Treated for Minimal Residual Disease.


948 3174 Iman Jilani

Transient Downmodulation of CD20 by Rituximab.


3507 3175 Marco Montillo

Sequential Subcutaneous Administration of CAMPATH-1H as Treatment of Minimal Residual Disease in CLL Patients Responding to Fludarabine (FAMP).


5638 3176 Marek Trneny

Combined Therapeutic Modality with Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose Therapy with Autologous Stem Cell Transplantation (ASCT) Leads to Excellent Response Rate and High Probability of Molecular Remission in CLL


451 3208 Niels W.C.J. Van de Donk

A Phase I/II Study of Bcl-2 Antisense (G3139) Combined with Vincristine, Adriamycin and Dexamethasone (VAD) in Patients with Refractory Multiple Myeloma.


4711 3211 Steven P. Treon

Pre-Therapy Serum IgM Levels Predict Clinical Response to Extended Rituximab in Waldenstroms Macroglobulinemia.


4682 3212 Paul Richardson

Thalidomide for Relapsed Multiple Myeloma after High Dose Therapy and Stem Cell Transplantation: Results of an Open-Label, Multicenter Phase Two Study of  Efficacy, Toxicity and Correlation with Biological Activity.


573 3234 Yong-Mi Kim

FTY720 Provides a New Approach for Separating Graft-Versus Host Disease (GvHD) from Graft-Versus-Tumor Effects.


3430 3236 William R. Drobyski

Elimination of Leukemia in the Absence of Lethal Graft Versus Host Disease after Allogeneic Bone Marrow Transplantation.


5148 3237 William R. Drobyski

Effect of Interleukin 7 Administration on Murine Graft Versus Host Disease and Allogeneic Marrow Engraftment.


2701 3242 Yasuyuki Iuchi

Effective Immunotherapy Using Dendritic Cells Pulsed with Heat Shock Protein Preparations Against Leukemia Cells after Syngenic Bone Marrow Transplantation in



3197 3243 Craig A. Mullen

Allogeneic Hematopoietic Stem Cell Transplant Recipients Do Not Acquire Tolerance to Antigens on Minimal Residual Lymphoblastic Lymphoma Tumor Cells and Can Respond to Post-Transplant Tumor Vaccines.


3572 3248 Benny J. Chen

Prevention of GVHD While Preserving GVL Effect after Selective Depletion of Host-Reactive T Cells by  photodynamic Cell Purging Process when Given as Delayed Lymphocyte Infusion.


4073 3253 Nadira Durakovic

Rational Use of Postgrafting Immunossuppression for the Induction of Mixed Hematopoietic Chimerism (MC) and Preservation of a Graft-Versus-Leukemia (GVL) Effect.


3653 3258 Patrick J. Stiff

Analysis of Risk Factors for Re-Mobilization Success in Patients Undergoing Autologous Stem Cell Transplants Who Fail an Initial Mobilization.


5348 3259 Steven M. Devine

Mobilization of Donors with GM-CSF Plus GCSF or GM-CSF Alone Results in Significantly Different Graft Composition Compared to G-CSF Alone.


4090 3260 Chirag R. Jani

Adhesion Receptor Expression on CD34+ Cells from Peripheral Blood or Bone Marrow Grafts: Correlation with Time to Engraftment.


3142 3261 Mamatha Karanth

Prospective Randomised Study of PBSC Mobilisation Using Intermediate Dose Cyclophosphamide and G-CSF Versus GCSF Alone.


4236 3262 Stephen J. Noga

Single Dose Pegfilgrastim Successfully Mobilizes Optimal Numbers of Autologous CD34+ Cells for Peripheral Blood Stem Cell Collection.


5031 3266 Paul Shaughnessy

Comparison between G-CSF and GM-CSF for Mobilization of Dendritic Cells, CD34+ Cells, and CD3+ Cells in Normal Donors.


2193 3267 O. Tournilhac

Fludarabine Plus Cyclophosphamide as Front Line Therapy in Chronic Lymphocytic Leukemia (CLL) Durably Impairs Steady State G-CSF Peripheral Blood Progenitor Cells (PBPC) Mobilization and Harvest.


4145 3268 Tamae Hamaki

Mobilization of Peripheral Blood Stem Cells (PBSC) from Healthy Donors: Daily Single Versus Divided Doses of G-CSF (filgrastim).


2264 3269 Peter Mollee

Effect of Gemcitabine, Dexamethasone and Cisplatin Salvage Chemotherapy (GDP) on Peripheral Blood Stem Cell (PBSC) Mobilization in Patients with Lymphoma.


3492 3270 Raymond Powles

Upfront Collection of Peripheral Blood Stem Cells (PBSC) in New Patients with Myeloma Receiving Minimal or No Prior Cytoreductive Therapy: Comparison of Two Regimes from Royal Marsden Hospital and St.

Bartholomews Hospital.


2703 3271 Chu-Myong Seong

Prospective CD34+ Cell Mobilization Trial Comparing SQ vs IV G-CSF on Normal Individuals.


5437 3274 Clarence B. Sarkodee- Adoo

Single Blinded, Randomized Study of Low-Dose Cyclophosphamide Followed by GCSF or Sequential GM-CSF/G-CSF for Mobilization of CD34+ Cells To Support Autologous Transplantation- Interim Analysis.


2986 3275 M. Tomblyn

Use of Total Leukocyte and Platelet Counts To Guide Stem Cell Apheresis in Healthy Allogeneic Donors Receiving G-CSF.


5594 3276 Osman Ilhan

Preapheresis Dendritic Cell Count Predicts Apheresis Content in Allogeneic PBSC Collection.


2504 3296 Jonathan W. Friedberg

High-Dose Chemotherapy, Autologous Stem Cell Transplantation (ASCT) and ExVivo Lymphoma Cell Purging Using BCell High Density Microparticles (HDM) Cell Separation System: PCR Does Not Accurately Predict Disease Recurrence in Patients


4950 3297 David A. Margolis

Rigorous T Cell Depletion Achieved by Single Step CD34 Selection Using the Isolex 300i with Version 2.5 Software; Experience in Healthy Donors.


5543 3298 Sagar Lonial

Three Methods of T-Cell Depletion of HPCT Products: Analysis of CD34+ Cell and Lymphocyte Purity and Recovery.


3916 3305 Maria Diez-Campelo

Impact of CD34+ Cell Dose on the Outcome of Patients Undergoing Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).


5166 3306 Joanne Filicko

Peripheral Blood Chimerism Predicts Bone Marrow Chimerism Following Nonmyeloablative Hematopoietic Progenitor Cell Transplant.


492 3307 Donald W. Bunjes

Radioimmunoconjugates: An Alternative Approach to Dose Reduced Conditioning.

2369 3339 Gina DiVenuti

Photopheresis as a Treatment for Chronic Graft-vs-Host Disease after Allogeneic Bone Marrow Transplantation.


2731 3340 Cesare G. Perotti

Extracorporeal Photochemotherapy (ECP): Treatment of Acute and Chronic Graft Versus Host Disease Both in Adults and Children.


5475 3341 Philippe Guardiola

Low-Dose Thoraco-Abdominal Irradiation for the Treatment of Refractory Chronic GvHD.


4640 3342 Debra M. Bensen-Kennedy

Primary Treatment Inconsistencies in Chronic Graft Versus Host Disease.


128 3349 Mohamad Mohty

High Doses of CD34+ Peripheral Blood Stem Cells Are Associated with Increased Mortality from Chronic Graft-Versus-Host Disease after Allogeneic HLA-Identical Sibling Transplantation.



4845 3350 Emiko Sakaida

Late-Onset Non-Infectious Pulmonary Complications (LONIPC) after Allogeneic Stem Cell Transplantation Are Significantly Associated with Chronic GVHD and Graft-

Versus-Leukemia (GVL) Effect.


4883 3355 Smita Bhatia

Hematopoietic Damage Persists Two Years after Autologous Peripheral Stem Cell Transplantation (aPBSCT) for Lymphoma.


4329 3359 Vikas Bhushan

Monitoring Therapy for Graft-Versus-Host Disease (GVHD) Following Hematopoietic Stem Cell Transplantation (HSCT). Response to  Glucocorticosteroids Predicted by Anti-CD3-Induced T Cell Apoptosis.


3777 3447 John A. Glaspy

Darbepoetin Alfa Is Cost Effective Compared to Epoetin Alfa for Treatment of Anemia in Cancer Patients  Receiving Chemotherapy.


Selected abstracts from the 2002 American Society of Hematology convention
Compiled by Greg Dafoe

[email protected]